DC‐based vaccines have become a central intervention in cancer treatment, where DC vaccines loaded with peptides (exogenous antigen sensitization) or genetically engineered vaccines (enhancing endogenous antigen expression and function) activate T cells to produce IFN‐γ and recruit NK/B cells, thereby inducing specific antitumor immune responses. Here, IFNG is linked to cancer.